AU2006243334A1 - Novel use of spiegelmers - Google Patents

Novel use of spiegelmers Download PDF

Info

Publication number
AU2006243334A1
AU2006243334A1 AU2006243334A AU2006243334A AU2006243334A1 AU 2006243334 A1 AU2006243334 A1 AU 2006243334A1 AU 2006243334 A AU2006243334 A AU 2006243334A AU 2006243334 A AU2006243334 A AU 2006243334A AU 2006243334 A1 AU2006243334 A1 AU 2006243334A1
Authority
AU
Australia
Prior art keywords
helix
nucleic acid
section
hmga
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006243334A
Other languages
English (en)
Inventor
Klaus Buchner
Dirk Eulberg
Florian Jarosch
Sven Klussmann
Christian Maasch
Werner Purschke
Axel Vater
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TME Pharma AG
Original Assignee
Noxxon Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noxxon Pharma AG filed Critical Noxxon Pharma AG
Publication of AU2006243334A1 publication Critical patent/AU2006243334A1/en
Priority to AU2012241062A priority Critical patent/AU2012241062A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/16Aptamers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
AU2006243334A 2005-05-04 2006-05-04 Novel use of spiegelmers Abandoned AU2006243334A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012241062A AU2012241062A1 (en) 2005-05-04 2012-10-11 Novel use of spiegelmers

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005020874.6 2005-05-04
DE102005020874 2005-05-04
PCT/EP2006/004180 WO2006117217A2 (de) 2005-05-04 2006-05-04 Neue verwendung von spiegelmeren

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012241062A Division AU2012241062A1 (en) 2005-05-04 2012-10-11 Novel use of spiegelmers

Publications (1)

Publication Number Publication Date
AU2006243334A1 true AU2006243334A1 (en) 2006-11-09

Family

ID=36928624

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006243334A Abandoned AU2006243334A1 (en) 2005-05-04 2006-05-04 Novel use of spiegelmers

Country Status (11)

Country Link
US (2) US8497250B2 (enExample)
EP (2) EP1877069A2 (enExample)
JP (2) JP2008540363A (enExample)
KR (2) KR101418369B1 (enExample)
CN (2) CN104293780A (enExample)
AU (1) AU2006243334A1 (enExample)
BR (1) BRPI0610367A2 (enExample)
CA (1) CA2607185A1 (enExample)
MX (1) MX2007013760A (enExample)
SG (1) SG161311A1 (enExample)
WO (1) WO2006117217A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
WO2008105773A2 (en) 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
JP5630998B2 (ja) 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008124639A2 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties
BRPI0817664A2 (pt) 2007-10-12 2015-03-24 Massachusetts Inst Technology Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
WO2010138193A2 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
US20130149314A1 (en) * 2010-02-09 2013-06-13 Jörn Bullerdiek p19Arf, HMGA2 and MDM2 For Use in the Diagnosis and Treatment of Aberrant Cell Growth
WO2011131371A1 (en) 2010-04-21 2011-10-27 Noxxon Pharma Ag Lipid binding nucleic acids
US20110293700A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
CN102375064A (zh) * 2010-08-26 2012-03-14 杭州华得森生物技术有限公司 用酶联免疫法检测人体中hmga2含量的体外诊断试剂盒
DE102010056610A1 (de) * 2010-12-31 2012-07-05 Volker A. Erdmann Pharmazeutische Zusammensetzung enthaltend L-DNA
CN109172819A (zh) 2011-07-29 2019-01-11 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞(ctl)免疫应答的合成纳米载体
JP2014533098A (ja) * 2011-10-21 2014-12-11 ノクソン・ファルマ・アクチエンゲゼルシャフト グルカゴン結合核酸
SG11201403769YA (en) * 2012-01-10 2014-07-30 Noxxon Pharma Ag Nucleic acids specifically binding cgrp
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
US9233119B2 (en) * 2012-09-27 2016-01-12 Miami University Use of HGMA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells
WO2014193964A2 (en) * 2013-05-28 2014-12-04 Marsha Rosner Prognostic and predictive breast cancer signature
US10679730B2 (en) 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
CA2936377A1 (en) 2014-01-10 2015-07-16 Shanghai Birdie Biotech, Inc. Compounds and compositions for treating egfr expressing tumors
EP4001311B1 (en) 2014-07-09 2025-11-05 Birdie Biopharmaceuticals Inc. Anti-pd-l1/pd-1 combinations for treating tumors
CN112546231A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
KR101755617B1 (ko) 2014-07-23 2017-07-10 한국과학기술연구원 삼차원 자기조립 핵산 나노입자 구조를 갖는 약물전달체
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
EP3233174B1 (en) * 2014-12-19 2021-03-31 Kemin Industries, Inc. Intraocular delivery of bioactive molecules using iontophoresis
CA2985818A1 (en) 2015-05-31 2016-12-08 Curegenix Corporation Combination compositions comprising an antagonist of porcupine and a pd-l/pd-1 axis antagonist for immunotherapy
EP3347051A4 (en) 2015-09-10 2019-04-24 Affigen, Inc. SEQUENCING SELECTING TUMOR THEROSTICAS
DE17829597T1 (de) * 2016-11-30 2019-12-05 Noxxon Pharma Ag Verfahren zur polyalkoxylierung von nukleinsäuren zur rückgewinnung und wiederverwendung einer überschüssigen polyalkoxylierungsreagenz
US20220033813A1 (en) * 2018-09-11 2022-02-03 The Texas A&M University System L-oligonucleotide inhibitors of polycomb repressive complex 2 (prc2)
CN115997124A (zh) * 2020-04-30 2023-04-21 维兰尼迪科技有限责任公司 用于检测生物或化学实体或事件的分子导线
CN112725438B (zh) * 2021-02-05 2023-08-22 深圳市宝安区妇幼保健院 子宫内膜息肉甲基化标志物组合、检测试剂盒及应用
CN114807183B (zh) * 2021-12-06 2023-06-02 西藏自治区农牧科学院农业研究所 一种青稞矢车菊素氧甲基转移酶基因的新用途
CN118311277B (zh) * 2024-06-11 2024-12-31 北京卫未科学技术有限公司 一种用于癌症早筛和辅助诊断的试剂盒及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622828A (en) * 1990-06-11 1997-04-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to secretory phospholipase A2 (sPLA2)
EP1793006A3 (en) * 1993-09-08 2007-08-22 Gilead Sciences, Inc. Nucleic acid ligands and improved methods for producing the same
DE69638099D1 (de) * 1995-05-04 2010-01-28 Gilead Sciences Inc Nukleinsäureligand-komplexe
US5780611A (en) * 1995-09-15 1998-07-14 Ramareddy Venkata Guntaka Oligomers which inhibit expression of collagen genes
US6171779B1 (en) 1996-07-12 2001-01-09 University Of Medicine & Dentistry Of New Jersey HMGI proteins in cancer
JP2001504448A (ja) * 1996-08-30 2001-04-03 フュルステ,イェンス,ペーター 核酸の鏡面対称選択および進化
DE19726186A1 (de) * 1997-06-20 1998-12-24 Boehringer Ingelheim Int Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
JP2004510829A (ja) * 2000-10-09 2004-04-08 バイエル アクチェンゲゼルシャフト 核酸を細胞内に転移させるための複合体
DE10118452A1 (de) * 2001-04-12 2002-10-31 Joern Bullerdiek Nukleinsäuresequenzen von Hyperplasien und Tumoren der Schilddrüse
ES2346640T4 (es) * 2001-10-26 2011-04-26 Noxxon Pharma Ag Ácido l-nucleico modificado.
WO2003051383A2 (de) * 2001-12-19 2003-06-26 Alcedo Biotech Gmbh Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
DE10211558A1 (de) * 2002-03-15 2003-10-09 Noxxon Pharma Ag Neue Formen RNAi
WO2003094973A1 (de) * 2002-05-08 2003-11-20 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Mittel und verfahren zum transport von biologisch aktiven molekülen in zellen
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
WO2004061456A2 (de) * 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Verwendungen von hmgb, hmgn, hmga proteinen
KR20060015505A (ko) * 2003-04-13 2006-02-17 엔존 파마슈티컬즈, 인코포레이티드 올리고뉴클레오타이드 전구약물
EP1628636A1 (de) * 2003-05-09 2006-03-01 Novosom AG Injizierbare liposomale depots zum wirkstoffdelivery
CA2526853A1 (en) * 2003-05-23 2005-03-03 Board Of Regents - The University Of Texas System Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting ap-1 transcription factors
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
WO2005072703A2 (en) * 2004-01-26 2005-08-11 Control Delivery Systems, Inc. Controlled and sustained delivery of nucleic acid-based therapeutic agents
WO2006069782A2 (en) * 2004-12-27 2006-07-06 Silence Therapeutics Ag. Lipid complexes coated with peg and their use

Also Published As

Publication number Publication date
EP1877069A2 (de) 2008-01-16
EP2206501A2 (de) 2010-07-14
US8497250B2 (en) 2013-07-30
WO2006117217A3 (de) 2007-08-09
CN101217967A (zh) 2008-07-09
KR101418369B1 (ko) 2014-07-24
CN101217967B (zh) 2014-09-10
JP2013224319A (ja) 2013-10-31
US20130337049A1 (en) 2013-12-19
WO2006117217A2 (de) 2006-11-09
US20090192100A1 (en) 2009-07-30
BRPI0610367A2 (pt) 2010-06-15
CN104293780A (zh) 2015-01-21
US9074214B2 (en) 2015-07-07
KR20080009276A (ko) 2008-01-28
CA2607185A1 (en) 2006-11-09
SG161311A1 (en) 2010-05-27
JP2008540363A (ja) 2008-11-20
KR101418367B1 (ko) 2014-07-25
EP2206501A3 (de) 2010-09-29
KR20140042941A (ko) 2014-04-07
MX2007013760A (es) 2008-01-28
JP5766750B2 (ja) 2015-08-19

Similar Documents

Publication Publication Date Title
US9074214B2 (en) Use of spiegelmers
EP3049523B1 (en) Multiaptamer target detection
Hollensen et al. circZNF827 nucleates a transcription inhibitory complex to balance neuronal differentiation
Coppotelli et al. The Epstein–Barr virus nuclear antigen-1 reprograms transcription by mimicry of high mobility group A proteins
Christian et al. Analysis of substrate recognition by the ribonucleoprotein endonuclease RNase P
van‘t Spijker et al. Ribosome profiling reveals novel regulation of C9ORF72 GGGGCC repeat-containing RNA translation
Duffy et al. Genome‐wide occupancy profiling reveals critical roles of FOXO1 in regulating extracellular matrix and circadian rhythm genes in human chondrocytes
Bunch et al. ERK2-topoisomerase II regulatory axis is important for gene activation in immediate early genes
US20060292560A1 (en) Transcription factor target gene discovery
Ranjith-Kumar et al. Single-stranded oligonucleotides can inhibit cytokine production induced by human toll-like receptor 3
AU2012241062A1 (en) Novel use of spiegelmers
HK1119388A (en) Novel use of spiegelmers
CN116970694B (zh) miR-9及其类似物在制备诊断和/或治疗细胞炎症的药物中的应用
Martín García et al. Alternative splicing regulation of cell-cycle genes by SPF45/SR140/CHERP complex controls cell proliferation
Gunaratne et al. Key RNA-binding domains in the La protein establish tRNA modification levels in Trypanosoma brucei
Stackpole et al. Ribosome profiling reveals novel regulation of GGGGCC repeat-containing RNA translation
Ryu et al. Reversible acetylation modulates p54nrb/NONO-mediated expression of the interleukin 8 gene
Kinnunen Transcription factor interactions and environment in wild type and pathogenic variants
Suresh Identification of Drug-Like Small Molecules that Bind RNAs and Targeted Degradation of RNAs
Swahn Role of Epithelial-Selective ETS Factors Mapping to Chr11p13 in Human Airway Epithelial Health
Class et al. Patent application title: Multiaptamer Target Detection Inventors: Urs A. Ochsner (Denver, CO, US) Louis S. Green (Lafayette, CO, US) Larry Gold (Boulder, CO, US) Nebojsa Janjic (Boulder, CO, US) Nebojsa Janjic (Boulder, CO, US) Evaldas Katilius (Superior, AZ, US)
HK1227430B (en) Multiaptamer target detection
HK1227430A1 (en) Multiaptamer target detection
MIGLIORI THE SYMMETRIC DIMETHYLATION OF HISTONE H3 ARGININE 2: A NOVEL HISTONE MARK INVOLVED IN EUCHROMATIN MAINTENANCE

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted